CI-1012

DRUG2 trials

Sponsors

Parke-Davis

Conditions

HIV Infections

Phase 1

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

CompletedNCT00002218

Parke-DavisHIV Infections

Target: 40Updated: 2005-06-24

A Study of CI-1012 in HIV-Infected Patients

CompletedNCT00002196

Parke-DavisHIV Infections

Target: 32Updated: 2005-06-24